Antidiabetic activity of N-(6-substituted-1,3-benzothiazol-2-yl)benzenesulfonamides
作者:Hermenegilda Moreno-Díaz、Rafael Villalobos-Molina、Rolffy Ortiz-Andrade、Daniel Díaz-Coutiño、Jose Luis Medina-Franco、Scott P. Webster、Margaret Binnie、Samuel Estrada-Soto、Maximiliano Ibarra-Barajas、Ismael León-Rivera、Gabriel Navarrete-Vázquez
DOI:10.1016/j.bmcl.2008.03.086
日期:2008.5
N-(6-Substituted-1,3-benzothiazol-2-yl)benzenesulfonamide derivatives 1-8 were synthesized and evaluated for their in vivo antidiabetic activity in a non-insulin-dependent diabetes mellitus rat model. Several compounds synthesized showed significant lowering of plasma glucose level in this model. As a possible mode of action, the compounds were in vitro evaluated as 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) inhibitors. The most active compounds (3 and 4) were docked into the crystal structure of 11 beta-HSD1. Docking results indicate potential hydrogen bond interactions with catalytic amino acid residues. (c) 2008 Elsevier Ltd. All rights reserved.
Synthesis, in vitro and computational studies of protein tyrosine phosphatase 1B inhibition of a small library of 2-arylsulfonylaminobenzothiazoles with antihyperglycemic activity
interactions between the nitrogroup in both compounds and the catalytic amino acid residues Arg 221 and Ser 216. Both compounds were evaluated for their in vivo antihyperglycemic activity in a type 2 diabetes mellitus rat model, showing significant lowering of plasma glucose concentration, during the 7 h post-intragastric administration.